Entrada Therapeutics, Inc.

NASDAQ:TRDA

Biotechnology

Healthcare
$5.03 +0.37%

+$0.03 today

Market cap
$196.93M
Beta
-0.26
P/E (TTM)
-1.7
EPS (TTM)
-$3.97
52W Low $4.93High $16.45

Volume 0.82M

Average 0.36M

Income Statement

Follow revenue through to earnings.

Revenue

$25.42M

FY 2025 · Annual

-87.9% YoY

Operating Income

-$156.00M

FY 2025 · Annual

Net Income

-$143.75M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00129.01M210.78M25.42M
Cost of Revenue00004.1M
Gross Profit00129.01M210.78M21.33M
Gross Margin——100.0%100.0%83.9%
Research & Development35.93M66.61M99.88M125.31M142.27M
Selling, General & Admin15.2M30.64M32.29M38.47M41.05M
Operating Expenses51.13M97.25M132.18M163.77M177.32M
Depreciation & Amortization1.12M1.9M2.84M3.77M425K
EBITDA(50.04M)(90.09M)14.9M70.26M(142.4M)
EBITDA Margin——11.5%33.3%-560.2%
Operating Income(51.13M)(97.25M)(3.16M)47.01M(156M)
Operating Margin——-2.5%22.3%-613.7%
Interest Income02.63M15.22M19.47M0
Interest Expense02.63M000
Other Income / Expenses(31K)2.63M15.22M19.47M13.17M
Income Before Tax(51.16M)(94.62M)12.06M66.49M(142.83M)
Pre-Tax Margin——9.3%31.5%-561.8%
Income Tax Expense0018.74M859K924K
Net Income(51.16M)(94.62M)(6.69M)65.63M(143.75M)
Net Margin——-5.2%31.1%-565.5%
EPS (Basic)(1.60)(2.79)(0.20)1.76(3.47)
EPS (Diluted)(1.60)(2.79)(0.20)1.68(3.47)
Weighted Avg Shares31.22M31.29M33.05M37.31M41.37M
Weighted Avg Shares (Diluted)31.22M31.29M33.05M39M41.37M

TRDA Earnings Waterfall · TTM

NASDAQ:TRDA · Revenue to Net Income

Key Ratios

EPS$-4.00
Gross Margin-534.2%
Net Margin-3124.7%
P/E Ratio-2.3
P/S Ratio305.6

Analysis

$5.7M of revenue converted into -$166.1M of net income for the selected period. Gross margin is -534.2% and net margin is -3124.7%, showing how much revenue survives after costs and taxes. EPS is $-4.00, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 5, 2026
8-KCurrent reportNov 5, 2026
8-KCurrent reportOct 14, 2026
SC 13D/ASC 13D/A filingSep 10, 2026
4Statement of changes in beneficial ownershipSep 9, 2026

How much revenue does TRDA generate?

Entrada Therapeutics, Inc. (TRDA) reported $25.42M of revenue in fiscal 2025.

Is TRDA profitable?

Entrada Therapeutics, Inc. (TRDA) reported -$143.75M of net income, with a net margin of -565.5%.